TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01446211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
Description: Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
Study: NCT00872625

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Study: NCT01656499

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arabinoxylanoligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Study: NCT02703363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study: NCT02371486

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound Scan
Description: Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina.
Study: NCT02703363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study: NCT00872625

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02371486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF Cycle
Description: Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IVF Cycle
Description: Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
Study: NCT04478786

Intervention type: OTHER
Intervention: Focus group discussion
Description: There is no intervention. This is a qualitative piece of work only.
Study: NCT00467363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic-acid (aspirin)
Description: 81mg of low-dose aspirin plus 400micrograms of folic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: 400micrograms of folic acid.
Study: NCT00872625

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study: NCT02078791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox infiltration
Description: botox cervical infiltration in a group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychology therapy
Description: Psychology problem solving therapy lead by specialized nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botox infiltration & psychology therapy
Description: Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
Study: NCT04078763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol with visual-auditory feedback
Description: The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol with visual feedback
Description: The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE protocol
Description: Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value
Study: NCT02703363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04453683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q. ILA insertion of proper size
Description: Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA insertion of proper size
Description: Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
Study: NCT00634556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa solution 2mg/ml for i.v. use
Description: 2mg/mL in normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study: NCT00742456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
Study: NCT00574652

Intervention type: DRUG
Group type: OTHER
Intervention: Proleukin
Description: 3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
Study: NCT02034591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT04078763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE protocol
Description: Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Matrix Test
Description: This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
Study: NCT02034591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Plus
Study: NCT00327535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
Study: NCT03036878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu
Description: ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Study: NCT04355286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemotrizinol
Description: Market-image topical sunscreen formulation containing BEMT (6%)
Study: NCT04848805

Intervention type: PROCEDURE
Intervention: liver transplantation
Description: total hepatectomy material was examined by pathology laboratory
Study: NCT00957853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
Study: NCT00327535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 6.3 micrograms/kg every 3 weeks
Study: NCT00957853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical tumor resection
Description: Surgical tumor resection on Day 10.
Study: NCT00327535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 9 micrograms/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 12 micrograms/kg every 3 weeks
Study: NCT01732692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Description: MOVIPREP solution

Intervention type: DRUG
Group type: OTHER
Intervention: MOVIPREP
Description: MOVIPREP solution
Study: NCT00957853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical tumor resection
Description: Surgical tumor resection on Day 10.
Study: NCT04078763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Matrix Test
Description: This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire
Description: 15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire
Description: 15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
Study: NCT02158572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: Transdermal contraceptive delivery system
Study: NCT00816036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Guideline Implementation
Description: 1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit.
Study: NCT04068883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q collar
Description: An externally-worn medical device that applies mild jugular compression
Study: NCT01027156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Description: In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
Study: NCT03228914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
Study: NCT02805998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT-I

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Study: NCT01107015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Patient Intervention
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-physician intervention
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient and PCP intervention with analyzed data
Description: Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
Study: NCT00458835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study: NCT00004980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Description: 132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site
Study: NCT02248376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel
Description: Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
Study: NCT02252861

Intervention type: OTHER
Intervention: Percutaneous Left Atrial Appendage Closure in routine care
Description: The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
Study: NCT01575990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making A Decision About CRC Screening
Description: Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Drivers 65 Plus
Description: This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
Study: NCT00740051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5mg once daily
Study: NCT02413762

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00795574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Study: NCT03212261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3RP-Lymphoma
Description: An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
Study: NCT00795574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Study: NCT00747513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle program
Description: a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
Study: NCT04439786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given the same volume of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Study: NCT02682758

Intervention type: DRUG
Group type: OTHER
Intervention: Xenon
Description: Wash-in of xenon for maintenance of anaesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Xenon
Description: Wash-in of xenon for maintenance of anaesthesia
Study: NCT02112201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated intervention for parents and adolescent girls
Description: The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
Study: NCT01067235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 add on Modafinil
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
Study: NCT00740051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin Placebo
Description: 0 mg placebo comparator for part 1 of study (to 18 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1-4mg for part 2 of study (weeks 19-52)
Study: NCT00308776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) infusion
Description: Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.